Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion

Braimah, Imoro Zeba; Singh, Sumit Randhir; Uplanchiwar, Bhushan; Mansour, Ahmad M.; Chhablani, Jay

doi:10.4103/ijo.ijo_1532_18

Cited by 5 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advent of anti‐VEGF IVTI has been a major advance in the treatment of macular diseases, to the extent that a Food and Drug Administration (FDA) approval has been obtained in only a few months following the Marina clinical study (Rosenfeld et al., 2006). Intravitreal injections (IVTI) have become the treatment of choice for macular diseases such as exudative age‐related macular degeneration (AMD) and diabetic macular oedema (Campochiaro et al., 2010; The Diabetic Retinopathy Clinical Research Network, 2015; Braimah et al., 2019). The beneficial effects on the visual acuity and tolerance are excellent (Heier et al., 2012).…”

Section: Introductionmentioning

confidence: 99%

A prospective multicentre study of intravitreal injections and ocular surface in 219 patients: IVIS study

Verrecchia

Chiambaretta²,

Kodjikian

et al. 2021

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose: To assess the impact of intravitreal injections (IVTI) on ocular surface of patients treated with multiple injections. Methods: Prospective, tricentric study conducted in patients treated with unilateral IVTI. An asepsis protocol with povidone-iodine was used for all patients during IVTI. The primary endpoint was the difference between the pre-IVTI Ocular Surface Disease Index (OSDI 1) score and that measured on day one (D1) post-IVTI (OSDI 2). Secondary endpoints were the evaluation of predictive factors for OSDI scores, pain assessment on D1, and the Lacrydiagâ analysis of tears from the injected eye versus contralateral eye before IVTI. Results: Two hundred and nineteen patients with a mean age of 75.9 AE 10 years were included. The mean OSDI2-OSDI1 difference was 19.2 AE 20.6 (p < 0.001). The mean noninvasive tear break-up time was 6.41 AE 4.59 seconds in the injected eye versus 7.36 AE 4.36 seconds in the contralateral eye (p < 0.001). In the multivariate analysis, the factors significantly associated with the OSDI 2 score were the OSDI 1 score (p < 0.001), the pain score on D1 (p < 0.001) the number of instilled glaucoma eye drop (p = 0.01) and a centre effect (centres 2 and 3 versus centre 1, p < 0.001). Conclusion: Our results confirm the impairment of the ocular surface and quality of life immediately after an IVTI. These results suggest 3 levels of action to improve the immediate tolerance: improving the basal status of the ocular surface, reducing the contact time with povidone-iodine that might be toxic to the surface, and improving immediate post-IVTI treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

A prospective multicentre study of intravitreal injections and ocular surface in 219 patients: IVIS study

Verrecchia

Chiambaretta²,

Kodjikian

et al. 2021

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion

Ang

Ah-Moye

Kim

et al. 2020

Eye

View full text Add to dashboard Cite

This review assessed the real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion (BRVO). A meta-analysis of 2530 eyes from 48 real-world studies of therapies for macular oedema secondary to BRVO was conducted. Baseline characteristics, visual, anatomical and safety outcomes were recorded. The weighted mean and weighted estimates from random-effects models were calculated for visual acuity (VA) and central subfield thickness (CST) changes at 6, 12 and 24 months. Primary outcome was change in VA (logMAR letters) at 12 months. Study quality was assessed using the quality appraisal checklist for case series developed by Institute of Health Economics. The mean baseline VA for the pooled data was 54.0 (51.5, 56.5) letters and the mean baseline CST was 501.3 (483.5, 519.1) µm. The random-effects estimate for mean (95% CI) change in VA was 14.6 (12.5, 16.7) letters at 12 months ( n = 1727). The random-effects estimate for mean (95% CI) change in CST was −181.7 (−230.7, −132.7) µm at 12 months ( n = 1325). The quality of studies varied considerably. Ocular and systemic adverse events were discussed in 79% and 42% of treatment arms respectively, with possible under-reporting. Visual and anatomical gains achieved in the real-world for anti-VEGF therapy were not as impressive as seminal RCTs, possibly due to reduced injection frequency in the real world and differences in baseline characteristics. There is an urgent need for consensus on the minimum efficacy, treatment burden and safety data to collect to strengthen the real-world evidence base.

show abstract

Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections

Singh

Chattannavar

Ayachit³

et al. 2019

Seminars in Ophthalmology

View full text Add to dashboard Cite

Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion

Cited by 5 publications

References 25 publications

A prospective multicentre study of intravitreal injections and ocular surface in 219 patients: IVIS study

A prospective multicentre study of intravitreal injections and ocular surface in 219 patients: IVIS study

A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion

Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections

Contact Info

Product

Resources

About